According
to a new market report published by Transparency Market Research
“CINV Existing and Pipeline Drugs Market - Global Industry
Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,”
the global CINV drugs market was valued at USD 1.28 billion in 2013
and is expected to grow at a CAGR of 5.7% from 2014 to 2020, to reach
an estimated value of USD 1.88 billion in 2020.
Browse
the full CINV Existing and Pipeline Drugs Market Report at
http://www.transparencymarketresearch.com/cinv-market.html
Chemotherapy
induced nausea and vomiting (CINV) refers to nausea and vomiting
associated with cancer chemotherapy. CINV is one of the most common
side effects experienced by cancer patients undergoing chemotherapy.
Although there are currently several drugs available to manage CINV,
this side effect continues to be a major concern for patients and
oncologists associated with chemotherapy. Companies such as Helsinn
Holding S.A., Heron Therapeutics, Inc. and Tesaro, Inc. are striving
to develop new and more efficacious therapeutic solutions to treat
CINV.
cinv-market
Aloxi
(palonosetron), Zofran (ondansetron), Kytril (granisetron) and Emend
(aprepitant) are the major available drugs which are used to manage
CINV. Recently in October 2014, U.S. FDA approved the first fixed
combination oral agent, Akynzeo (developed by Helsinn Holding S.A.)
for the prevention of CINV. Akynzeo, being the first fixed-dose
combination providing patients with two antiemetics in a single dose,
is likely to offer better patient compliance and consequently is
expected to witness increasing popularity among physicians.
SUSTOL
(APF-530) and rolapitant are the two major CINV pipeline drugs that
are currently under phase III or registration phase and would be
introduced in the near future. Approval of these two pipeline drugs
will be driving the overall CINV drugs market during the forecast
period from 2014 to 2020. In addition to this, continuous increase in
number of patients undergoing chemotherapy is also expected to play a
key role in the growth of CINV drugs market. Various sources indicate
that approximately 70% to 80% cancer patients on chemotherapy exhibit
nausea and vomiting as major side effects.
Two
key CINV drugs Aloxi and Emend are going off-patent in 2015, post
which a number of generic manufacturers are likely to enter in the
market with generic versions of these two brands. Therefore, patent
expiry of Aloxi and Emend has been anticipated to affect market
revenue during the forecast period, as their generic versions will be
sold at 80% to 85% lower prices than the branded ones.
Browse
the full Press Release Report :
Geographically,
North America was the largest regional market for CINV drugs in 2013
with a market share of over 45% of the total revenue generated
globally, followed by Europe. North America it is expected to retain
its leading position through 2020, growing at a CAGR of more than 7%
during the forecast period from 2014 to 2020. On the other hand, the
CINV drugs market in Asia-Pacific would be primarily driven by the
increasing penetration of western companies coupled with the growing
number of cancer patients. In many countries in Asia-Pacific and Rest
of the World (RoW) regions, generic manufacturers would be competing
with the branded CINV drug manufacturers. Owing to the low purchasing
power of people, generic versions of expired branded drugs are in
greater demand in the region.
GlaxoSmithKline
plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co.,
Inc. and Tesaro, Inc. are some of the key players actively
participating in the CINV drugs market.
The
global CINV existing and pipeline drugs market is segmented as
follows:
CINV
Existing and Pipeline Drugs Market Revenue (USD Million), by Major
Drugs
Aloxi
(palonosetron)
Zofran
Generic (ondansetron)
Kytril
Generic (granisetron)
Emend
(aprepitant)
Akynzeo
(netupitant-palonosetron)
SUSTOL
(extended release granisetron injection)
Rolapitant
CINV
Existing and Pipeline Drugs Market Revenue (USD Million), by
Geography
North
America
Europe
Asia-Pacific
Rest
of the World (RoW)
Request
a Brochure of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=776
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather,
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Mr.Nachiket
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
No comments:
Post a Comment